Independent fund research. Built on SEC filings.

How we research funds

Mutual fund · Small-Cap · Driehaus Mutual

Driehaus Micro Cap Growth Fund (DMCRX)

Ticker DMCRX · · Holdings as of Jun 30, 2026

5-yr return
+9.6%annualized
1-yr return
+30.9%as of Dec 2025
Net assets
$596.7Mall share classes
Holdings
133

Bottom line

Is DMCRX a good fund? The bottom line

DMCRX is an actively managed small-cap mutual fund from Driehaus Mutual.

It returned +30.9% over one year, +9.6% a year over five years, +19.6% a year over ten (as of Dec 31, 2025, per its prospectus).

With $597 million in net assets and 133 holdings, its largest position is Definium Therapeutics Inc (2.4%) and the top 10 make up 17.9% of the portfolio.

What stands out

  • 5-year return beat 77% of category peers
  • No front-end sales load

What to watch

  • High turnover (142% a year) can mean more taxable distributions

Updated Nov 19, 2026

What DMCRX invests in

Driehaus Micro Cap Growth Fund seeks to maximize capital appreciation.

The Fund uses a growth style of investment in equity securities, including common stocks and other equity securities of issuers. Under normal market conditions, the Fund invests at least 80% of its net assets (plus the amount of borrowings for investment purposes) in the equity securities of U.S. micro-capitalization (micro-cap) companies. For purposes of the Fund, the investment adviser considers a company to be a micro-cap company if it is within the same market capitalization range at the time of investment as those included in the Russell Microcap Growth Index. For the avoidance of doubt, while the reference index is float-adjusted, meaning it excludes closely held and other shares unavailable to investors, the investment adviser does not consider a float-adjustment when determining the market capitalization of a company. As of March 31, 2026, approximately 87% of the Russell…

From the fund's prospectus (filed Apr 29, 2026).

DMCRX performance

Fund calendar-year total returns, 2016–2025 2016: +17.8%; 2017: +24.3%; 2018: +3.9%; 2019: +33.9%; 2020: +85.6%; 2021: +24.7%; 2022: −33.5%; 2023: +11.4%; 2024: +30.6%; 2025: +30.9% +18% 2016 +24% 2017 +4% 2018 +34% 2019 +86% 2020 +25% 2021 −34% 2022 +11% 2023 +31% 2024 +31% 2025
Fund gain (+) Fund loss (−)
Average annual total returns
1 yr5 yr10 yr
DMCRX+30.9%+9.6%+19.6%
Small-Cap median+7.6%+7.0%+9.2%

Source: Fund prospectus, as of Dec 31, 2025

Full DMCRX performance history →

DMCRX top 10 holdings

#Holding% of fund
1Definium Therapeutics Inc DFTX2.43%
2Praxis Precision Medicines Inc PRAX2.06%
3Spyre Therapeutics Inc SYRE2.00%
4Ultra Clean Holdings Inc UCTT1.95%
5Cardinal Infrastructure Group Inc CDNL1.90%
6Ceco Environmental Corp CECO1.73%
7Nlight Inc LASR1.57%
8Xometry Inc XMTR1.49%
9Silicon Motion Technology Corp SIMO1.42%
10Edgewise Therapeutics Inc EWTX1.41%

Source: SEC Form N-PORT, period ended Jun 30, 2026

The top 10 make up 17.9% of the fund. See all top 25 holdings and asset mix →

Alternatives to DMCRX

More funds like DMCRX →

DMCRX FAQ

Is DMCRX a good investment?
It depends on your goals, but the data points to: 5-year return beat 77% of category peers; no front-end sales load; high turnover (142% a year) can mean more taxable distributions. This is general information, not personalized advice.
What does DMCRX hold?
DMCRX's largest holdings are Definium Therapeutics Inc (2.4%), Praxis Precision Medicines Inc (2.1%), Spyre Therapeutics Inc (2.0%), Ultra Clean Holdings Inc (1.9%), Cardinal Infrastructure Group Inc (1.9%). It holds 133 positions in total as of Jun 30, 2026 (SEC Form N-PORT).
What is DMCRX's 5-year return?
DMCRX returned +9.6% a year over the five years ending Dec 31, 2025, and +19.6% a year over ten years. Past performance does not guarantee future results.
Does DMCRX have a sales load?
No. DMCRX has no front-end sales charge.
Who manages DMCRX?
DMCRX is offered by Driehaus Mutual through Driehaus Mutual Funds.